MK

Mauna Kea Technologies SASOOTC MKEAF Stock Report

Last reporting period 31 Dec, 2022

Updated 28 Aug, 2024

Last price

Market cap $B

0.033

Micro

Exchange

OOTC - OTC

MKEAF Stock Analysis

MK

Uncovered

Mauna Kea Technologies SAS is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-38/100

Low score

Market cap $B

0.033

Dividend yield

Shares outstanding

44.508 B

Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2011-07-05. The firm focuses on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product is Cellvizio, a confocal laser endomicroscopy platform using microprobes and needles. This technological platform enables to view tissues at cellular level, in real time, during standard procedure. Cellvizio can be used in gastroenterology, pulmonology, or urology. The firm markets its technological platform in more than 40 countries, including the United States, Europe, Japan, China, South Korea as well as several Latin American countries.

View Section: Eyestock Rating